Androgen regulation of 5α-Reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Li, Jin ^a   Ding, Zhiyong ^a   Wang, Zhengxin ^a   Lu, Jing Fang ^a   Maity, Sankar N ^a   Navone, Nora M ^a   Logothetis, Christopher J ^a   Mills, Gordon B ^a   Kim, Jeri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ISOENZYME; SMALL INTERFERING RNA; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CHOLESTENONE 5ALPHA REDUCTASE; DACTINOMYCIN; MEMBRANE PROTEIN; MESSENGER RNA; SRD5A3 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER PREVENTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MARKER GENE; MOLECULAR PATHOLOGY; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SRD5A1 GENE; SRD5A2 GENE; SRD5A3 GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CHOLESTENONE 5 ALPHA-REDUCTASE; DACTINOMYCIN; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355168638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028840     Document Type: Article

References (49)

1. Fitzpatrick JM, Schulman C, Zlotta AR, Schroder FH, (2009) Prostate cancer: a serious disease suitable for prevention. BJU Int 103: 864-870.
2. Pienta KJ, Bradley D, (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671.
3. Scher HI, Sawyers CL, (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
4. Zhu YS, Imperato-McGinley JL, (2009) 5α-Reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 1155: 43-56.
5. Wilson EM, French FS, (1976) Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 251: 5620-5629.
6. Wilbert DM, Griffin JE, Wilson JD, (1983) Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56: 113-120.
7. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB, (2003) Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57: 134-139.
8. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, et al. (2005) Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63: 231-239.
9. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, et al. (1997) Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82: 2210-2214.
10. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, et al. (2008) Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99: 81-86.
11. Titus MA, Mohler JL, (2009) 5α-Reductase Isozymes in Castration-Recurrent Prostate Cancer. Androgen Action in Prostate Cancer, Springer New York: Part 2, 175-185.
12. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, et al. (2011) 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 71: 1033-1046.
13. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, et al. (2010) SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142: 203-217.
14. Morava E, Wevers RA, Cantagrel V, Hoefsloot LH, Al-Gazali L, et al. (2010) A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism. Brain 133: 3210-3220.
15. Kahrizi K, Hu CH, Garshasbi M, Abedini SS, Ghadami S, et al. (2011) Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3. Eur J Hum Genet 19: 115-117.
16. Stoner E, (1990) The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 37: 375-378.
17. Tian G, Mook RA Jr, Moss ML, Frye SV, (1995) Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 34: 13453-13459.
18. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224.
19. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, et al. (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172: 1314-1317.
20. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, et al. (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192-1202.
21. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT, (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12: 4072-4079.
22. Makridakis N, Reichardt JKV, (2005) Pharmacogenetic analysis of human steroid 5α reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol 34: 617-623.
23. Makridakis NM, di Salle E, Reichardt JKV, (2000) Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II. Pharmacogenetics 10: 407-413.
24. George FW, (1997) Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. Endocrinology 138: 871-877.
25. Steiner JF, (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30: 16-27.
26. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R, (2008) Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72: 808-812.
27. George FW, Russell DW, Wilson JD, (1991) Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase. Proc Natl Acad Sci U S A 88: 8044-8047.
28. Pratis K, O'Donnell L, Ooi GT, Stanton PG, McLachlan RI, et al. (2003) Differential regulation of rat testicular 5α-reductase type 1 and 2 isoforms by testosterone and FSH. J Endocrinol 176: 393-403.
29. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, et al. (1994) Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152: 433-437.
30. Zhou Z, Speiser PW, (1999) Regulation of HSD17B1 and SRD5A1 in lymphocytes. Mol Genet Metab 68: 410-417.
31. Melcangi RC, Poletti A, Cavarretta I, Celotti F, Colciago A, et al. (1998) The 5alpha-reductase in the central nervous system: expression and modes of control. J Steroid Biochem Mol Biol 65: 295-299.
32. Torres JM, Ortega E, (2003) Precise quantitation of 5α-reductase type 1 mRNA by RT-PCR in rat liver and its positive regulation by testosterone and dihydrotestosterone. Biochem Biophys Res Commun 308: 469-473.
33. Torres JM, Ortega E, (2003) Differential regulation of steroid 5α-reductase isozymes expression by androgens in the adult rat brain. Faseb J 17: 1428-1433.
34. El-Awady MK, El-Garf W, El-Houssieny L, (2004) Steroid 5α reductase mRNA type I is differentially regulated by androgens and glucocorticoids in the rat liver. Endocr J 51: 37-46.
35. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, et al. (2009) Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res 37: D925-932.
36. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, et al. (2011) Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71: 846-856.
37. Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, et al. (1981) The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol 114: 804-816.
38. Reddy GK, (2004) Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. Clin Prostate Cancer 2: 209-211.
39. Wilson JD, (1996) Role of dihydrotestosterone in androgen action. Prostate Suppl 6: 88-92.
40. Noss KR, Wolfe SA, Grimes SR, (2002) Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 285: 247-256.
41. Qi W, Gao S, Wang Z, (2008) Transcriptional regulation of the TGF-β1 promoter by androgen receptor. Biochem J 416: 453-462.
42. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, et al. (2008) Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 61: 448-454.
43. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, et al. (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14: 2257-2260.
44. Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, et al. (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-κB signalling in prostate cancer cells. Biochem J 379: 421-431.
45. Zhang M, Magit D, Sager R, (1997) Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci U S A 94: 5673-5678.
46. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, et al. (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47: 52-58.
47. Reid J, Murray I, Watt K, Betney R, McEwan IJ, (2002) The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF. J Biol Chem 277: 41247-41253.
48. Chesire DR, Isaacs WB, (2002) Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21: 8453-8469.
49. Yamana K, Labrie F, Luu-The V, (2010) Human type 3 5αreductase is expressed in peripheral tissues at higher levels than type 1 and type 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Invest 2: 293-299.